obesity
Conditions
Interventions
sodium glucose cotransporter 2 inhibitor (SGLT2i):dapagliflozin 10mg qd
Sulfonylurea : glipizide10mg qd
Sponsors
Shantou Central Hospital
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients with newly diagnosed type 2 diabetes who are aged between 20 and 75 years old, with BMI >= 24 kg/m² or waist-to-height ratio > 0.5;Participation in this study is voluntary, and all subjects provide written informed consent
Exclusion criteria
Exclusion criteria: 1 Patients diagnosed with diabetes other than type 2 diabetes; 2 Patients with diabetes complicated by severe complications, including diabetic ketoacidosis, hyperosmolar hyperglycemic syndrome, lactic acidosis; 3 Patients with chronic active hepatitis and/or severe liver dysfunction, liver cirrhosis, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding the upper limit of normal by more than 3 times, or serum total bilirubin levels greater than 34.2 µmol/L (greater than 2.0 mg/dl); 4 Patients with a history of kidney disease or features of kidney damage, including unstable or rapidly progressive kidney disease, moderate/severe kidney damage or end-stage kidney disease, estimated glomerular filtration rate (eGFR) = 133 µmol/L (>= 1.50 mg/dl), female subjects with serum Cr >= 124 µmol/L (> 1.40 mg/dl); 5 Patients with myocardial infarction, cerebral infarction, cardiac surgery or vascular reconstruction (coronary artery bypass grafting/percutaneous transluminal coronary angioplasty) within the past 12 weeks, unstable angina pectoris, congestive heart failure (NYHA class III or IV), transient ischemic attack or major cerebrovascular disease; 6 Patients with gastrointestinal diseases or surgical history, including intestinal obstruction, intestinal ulcer, bariatric surgery, waist belt surgery, gastrointestinal anastomosis, intestinal resection; 7 Pregnant or lactating women; 8 Patients with urinary tract infection within the past 2 weeks; 9 Subjects considered by the investigators to be unlikely to comply with the study protocol, or patients with serious physical or psychological diseases that may affect the validity or safety of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Waist-to-height ratio;Body Mass Index;Analysis of intestinal flora in stool; | — |
Secondary
| Measure | Time frame |
|---|---|
| waist-to-hip ratio;body composition analysis;visceral fat area measurement;subcutaneous fat area measurement;C-reactive protein;2h-insulin;routine urianlysis;albumin-to-creatinine ratio; | — |
Countries
China
Contacts
Public ContactShuhui Yang
Shantou Central Hospital
Outcome results
None listed